Immunohistochemical profile and morphology in triple - Negative breast cancers

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 7, 2013, Pages 1361-1365

  Rao, Chandrika ^a   Shetty, Jayaprakash ^a   Kishan Prasad, H L ^a  

^a NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

Basal like; Breast cancer; CK 5 6; EGFR; Triple negative

Indexed keywords

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; PHENOTYPE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR NECROSIS;

EID: 84879978653     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5823.3129     Document Type: Article

References (24)

1. Badve S, Dabbas DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157-167.
2. Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, HER2 and CK 5/6 in Infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2009;10:773-778.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10: 5367-5374.
4. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123: 236-240.
5. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL et al. Protocol for the examination of specimens with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133:1515-1538.
6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907-922.
7. Gutierrez C, Schiff R. HER2 Biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:55-62.
8. Choccalingam C, Rao L, Rao S. Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India. Breast cancer (Auckl). 2012;6:21-29.
9. Keam B, Im S, Lee K, Han S, Oh D, Kim J et al. Ki-67 can be used for further classification of triple-negatvie breast cancer into two subtypes with different response and prognosis. Breast Cancer Research. 2011; 13:R22.
10. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of Triple-negative breast cancer: Experience in an Asian developing country. Asian Pac J Cancer Prev. 2009;10:395-398.
11. Dent R, Trudeau M, Pritchand KI, Hanna WM, Khan HK, Sawka CA et al. Triple-negative breast cancer: Clinical features and pattern of recurrence. Clin Cancer Res. 2007;13:4429-4434.
12. Rakha EA, El-Sayed ME, Green AR, Lee AH Robertson JF, Ellis IO. Prognostic markers in Triple negative breast cancer. Cancer 2007;109:25-32.
13. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopatholgy 2008;52:108-118.
14. AA Thike, Cheok Py, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathol. 2010;23:123-133.
15. Liu S, Lachapelle J, Leug S, Gao D, Foulkes WD, Neilsen TO. CD8+ lymphocytic infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast cancer Res. 2012;14:R48.
16. Mouawad R, Spano JP, Khayat D. Lymphocytic infiltration in breast cancer: A key prognostic factor that should not be ignored. J Clin Oncol. 2011;29:1935-1936.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492-2502.
18. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and longterm survival. Breast cancer Res. 2007;9:R4.
19. Popovska SL, Ooi A, Ivanov IN, Ivanova NG, Dineva TB. Triple-negative breast cancer does not fully overlap with "Basal-like" molecular profile - A morphological and immunohistochemical study. J Biomed Clin Res. 2010;3:45-50.
20. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B et al. Triple negative breast cancer: Outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol. 2010;34: 956-964.
21. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olapade OI, Moore DT et al. Phenotypic evaluation of the bal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
22. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.
23. Winter J. Morphological and immunophenotypic analysis of basal-like carcinoma of the breast. Bioscience Horizons. 2008;19-27.
24. Zhou X, Liu Q. Clinicopathological characteristics of Triple-negative breast cancer. Chin J Cancer Res. 2010;22:17-20.